Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study

Review Medicine, General & Internal

Biologic Therapies for Severe Asthma

Guy G. Brusselle et al.

Summary: Biologic therapies may be necessary to reduce the disease burden and risks for severe asthma patients. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Allergy

Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis

Giorgio Walter Canonica et al.

Summary: The study showed that benralizumab can improve symptoms of NP and asthma outcomes in patients with severe, eosinophilic asthma and NP, with better effects observed in patients with high baseline SNOT-22 scores.

ALLERGY (2022)

添加到收藏夹

Article Critical Care Medicine

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

Michael E. Wechsler et al.

Summary: The study assessed the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma over 96 weeks of treatment. The findings demonstrated good safety and efficacy during the study period, supporting the long-term use of dupilumab in this patient population.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Review Allergy

Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Celeste M. Porsbjerg et al.

Summary: The study identified significant differences in prescription criteria for biologics among 28 countries, posing a challenge to the implementation of personalized medicine for severe asthma treatment globally.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

添加到收藏夹

Article Allergy

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Andrew N. Menzies-Gow et al.

Summary: This study described real-life patterns of biologic use for severe asthma in multiple countries, showing that most patients continued their initial biologic treatment, while some stopped or switched to a different biologic. Patients who stopped or switched were more likely to have higher baseline blood eosinophil count, higher exacerbation rate, lower lung function, and greater healthcare resource utilization.

JOURNAL OF ASTHMA AND ALLERGY (2022)

添加到收藏夹

Article Allergy

Anti-Interleukin-5 Therapy Is Associated with Attenuated Lung Function Decline in Severe Eosinophilic Asthma Patients From the Belgian Severe Asthma Registry

Sophie Graff et al.

Summary: Asthmatics experience accelerated lung function decline, but the addition of anti-IL-5 therapy can attenuate this decline. Asthma control, late-onset asthma, and the use of anti-IL-5 are associated with a lower decline in lung function.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

添加到收藏夹

Article Allergy

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life

Francesco Menzella et al.

Journal of Asthma and Allergy (2022)

添加到收藏夹

Article Allergy

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study

Takanori Numata et al.

Summary: This retrospective study of 97 patients receiving biologic therapy for severe asthma found that switching between biologics may be an effective treatment option, especially for patients in whom initial biologic therapy is ineffective.

JOURNAL OF ASTHMA AND ALLERGY (2021)

添加到收藏夹

Article Allergy

Quantification of Glucocorticoid-Associated Morbidity in Severe Asthma Using the Glucocorticoid Toxicity Index

P. Jane McDowell et al.

Summary: The GTI is a useful tool for systematically capturing and quantifying GC toxicity at the individual patient level in severe asthma. GC toxicity varies widely between individual patients with SA and correlates only modestly with GC exposure over the preceding year. Age and mini-AQLQ are better predictors of GC toxicity. The GTI and MCID will facilitate assessment of individual SA response to steroid-sparing agents in clinical trials and routine care.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

Michael E. Wechsler et al.

Summary: The study found that the monoclonal antibody itepekimab targeting interleukin-33 was more effective than placebo in improving lung function and reducing the incidence of loss of asthma control events in patients with moderate-to-severe asthma.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy

Corrado Pelaia et al.

Summary: The study suggests that switching from omalizumab to benralizumab may be a valuable therapeutic approach for allergic patients with severe eosinophilic asthma who are not adequately controlled by anti-IgE treatment, leading to significant improvements in asthma exacerbation rate, rescue medication need, asthma control test score, lung function, and blood eosinophil count.

BIOMEDICINES (2021)

添加到收藏夹

Article Allergy

Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

John W. Upham et al.

Summary: Using a modified Delphi process, severe asthma experts developed an international consensus-based definition of a severe asthma super-responder, with major and minor criteria established. This definition is crucial for better understanding the prevalence, predictive factors, and mechanisms involved in super-responders, emphasizing the need for further research in these areas.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Meeting Abstract Respiratory System